Design Therapeutics, Inc. (DSGN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$15.14+0.73%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · DSGN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
DSGN — litigation filed
Dated 2026-05-18
Other Events. On May 18, 2026, Design Therapeutics, Inc. (the “Company”) announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (“FA”). RESTORE-FA Key Data Highlights RESTORE-FA is a Phase 1/2 clinical trial evaluating DT-216P2 in patients with FA, designed to assess safety, pharmacokinetics, pharmacodynamics, and exploratory clinical endpoints. As of May 17, 2026, 16 patients had completed treatment with weekly…
Why it matters: If revenue growth speeds up, it may signal a positive shift for Design Therapeutics.
Supportive ifHealth Care sector revenue growth is speeding up toward 10% or more.
Worry ifRevenue growth keeps slowing down below 10%.
Why it matters: Updates on cash use will show if the company is getting better financially.
Supportive ifManagement shares a clear plan to lower cash use and operating costs.
Worry ifManagement provides no new plan or worsens cash burn guidance.
Why it matters: An update on registrational plans could signal progress in bringing DT-216P2 to market. This is key for investor confidence.
Supportive ifManagement shares a clear plan for DT-216P2's registration.
Worry ifManagement is slow to share news about registration plans.
Why it matters: Managing cash burn is critical. High cash burn could raise concerns about sustainability.
Worry ifThe company reported an operating cash burn of less than negative $16.4M in Q2 2026.
Less concerning ifThe company reported an operating cash burn of more than negative $16.4M in Q2 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$198 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $707 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,559 loss on $10,000 · 35.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Cash reserves and burn rate affect the company's ability to fund ongoing trials. A significant drop could signal trouble.
Worry ifCash reserves stay stable or grow, showing good financial health.
Less concerning ifCash reserves fall below $200 million or burn rate rises sharply.
Why it matters: Monitoring cash burn is critical to ensure the company can fund its operations and clinical trials. High burn rates could signal financial trouble.
Worry ifCash burn drops a lot compared to earlier quarters.
Less concerning ifCash burn goes up or stays high, showing bad expense control.
Why it matters: Data from this trial will show the potential of DT-818 in treating myotonic dystrophy type 1. Positive results could enhance the pipeline.
Supportive ifData shows strong safety and effectiveness results from the DT-818 trial.
Worry ifData shows no strong safety or effectiveness results from the DT-818 trial.
Why it matters: Starting this trial is key for advancing treatment options for myotonic dystrophy type-1.
Supportive ifAnnouncement of successful dosing of the first patient in the DT-818 Phase 1 trial.
Worry ifDelay in starting the trial or failure to dose the first patient by mid-2026.
Why it matters: This data is key to understanding how well DT-216P2 treats Friedreich ataxia. Good results could help its development.
Supportive ifData shows a big rise in frataxin levels after 12 weeks of treatment.
Worry ifData shows no rise or a drop in frataxin levels after 12 weeks.
Why it matters: Data from the DT-168 trial is key to seeing its potential for Fuchs dystrophy. Delays could affect how investors feel.
Watch forData shows positive safety and biomarker results from the DT-168 trial.
Also watch forData shows negative results or further delays in the DT-168 trial.
Why it matters: Advancing DT-216P2 is key for growth. Positive trial results could boost confidence.
Supportive ifThe company announced good results from the Phase 1/2 RESTORE-FA trial.
Worry ifNegative results or delays in the RESTORE-FA trial.
Why it matters: Updates on DT-818's trial could show a new treatment for myotonic dystrophy. Good news may help investors.
Supportive ifManagement shares good early results from the Phase 1 trial of DT-818 in patients.
Worry ifNo updates or negative trial results reported for DT-818.
Why it matters: The results will show if DT-216P2 can effectively increase frataxin levels in patients. This is crucial for the Friedreich ataxia program's success.
Supportive ifAn update shows a big rise in frataxin levels in trial patients.
Worry ifNo big change in frataxin levels, or trial results are late.
Why it matters: Updates on this trial will show progress in treating Fuchs corneal dystrophy. Delays may hurt investor confidence.
Watch forManagement shares good interim results from the DT-168 trial.
Also watch forManagement reports more delays or bad results from the DT-168 trial.
Why it matters: A big drop in cash reserves could slow clinical development. This raises worries about finances.
Worry ifCash reserves are below $200 million. This shows tighter financial conditions.
Less concerning ifCash reserves are above $200 million. This shows financial stability.